ClinicalTrials.gg
Drug

Spesolimab clinical trials

Also written BI 655130 and Spevigo®.

studies test it
32
open now
1
in phase 3
7
first study started
2015

How each study uses spesolimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the spesolimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
1 Sept 2022 · SPEVIGO · BLA 761244 (FDA, Drugs@FDA)
European Union
9 Dec 2022 · Spevigo · EMEA/H/C/005874 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Spesolimab
24
Spesolimab - solution for infusion
2
BI 655130 (spesolimab)
2

Brand

Spevigo®
2

Development codes

BI 655130
11

Studies by the year they started

32 studies that test it; most in 2019 (6)

Studies that test spesolimab, by start year
YearStudies
20151
20162
20175
20182
20196
20204
20213
20222
20234
20242
20251

By phase

A phase 1/2 study counts in both.

Phase 1
7
Phase 2
21
Phase 3
7
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 31 · Other 1

Boehringer Ingelheim (28) · LEO Pharma (3) · Icahn School of Medicine at Mount Sinai (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2, 1 in phase 3

Studies that test spesolimab, phase 3 first.

Studies

Open first, then newest update. How each study uses spesolimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 32

See all 32 studies that test spesolimab →

Codes

What other systems call spesolimab · ClinicalTrials.gg INT001523

  • MeSH (NLM) C000712973spesolimabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 5IB2J79MCXSPESOLIMABConfirmed FDA, NLM, Wikidata
  • RxNorm 2610417One source FDA
  • Wikidata Q111172579spesolimabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C166849SpesolimabOne source FDA
  • DrugBank DB15626One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.